Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

5.45
+0.30005.83%
Post-market: 5.450.00000.00%19:58 EDT
Volume:1.34M
Turnover:7.20M
Market Cap:753.40M
PE:-1.29
High:5.48
Open:5.25
Low:5.18
Close:5.15
Loading ...

Stock Track | Vir Biotechnology Plummets 5.43% as Q1 Earnings Miss Estimates, Revenue Drops 94.6%

Stock Track
·
08 May

Stock Track | Vir Biotechnology Surges 6.24% Pre-market Despite Quarterly Loss, Analyst Optimism Prevails

Stock Track
·
08 May

Vir Biotechnology Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Vir Biotechnology Q1 EPS $(0.88), Inline, Sales $3.03M Miss $8.59M Estimate

Benzinga
·
08 May

BRIEF-Vir Biotechnology Q1 EPS USD -0.88

Reuters
·
08 May

Vir Biotechnology Inc: Expects Its Cash, Cash Equivalents and Investments to Fund Its Operations Into Mid-2027

THOMSON REUTERS
·
08 May

Vir Biotechnology Inc expected to post a loss of 84 cents a share - Earnings Preview

Reuters
·
06 May

Vir Biotechnology (VIR) Gets a Buy from H.C. Wainwright

TIPRANKS
·
01 May

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Business Wire
·
01 May

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (Easl) Congress 2025

THOMSON REUTERS
·
24 Apr

Vir Biotechnology Is Maintained at Buy by Goldman Sachs

Dow Jones
·
18 Apr

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple

Insider Monkey
·
09 Apr

Pharma Stocks Sink After Trump Says "Major" Tariffs Are Coming

Tiger Newspress
·
09 Apr

Pharma Stocks Survive Market Rout on Tariff Exemption, but Uncertainty Continues

Reuters
·
03 Apr

Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution

Simply Wall St.
·
31 Mar

Pharma Stocks Sink After Ouster of Top FDA Vaccine Regulator

Reuters
·
31 Mar

BRIEF-Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection

Reuters
·
13 Mar

Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial

MT Newswires Live
·
13 Mar

Vir Biotechnology Enrolls First Patient in Phase 3 Eclipse Registrational Program for Chronic Hepatitis Delta

THOMSON REUTERS
·
13 Mar

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Business Wire
·
13 Mar